Skip to main content
Vera Therapeutics, Inc. logo

Vera Therapeutics, Inc. — Investor Relations & Filings

Ticker · VERA ISIN · US92337R1014 US Professional, scientific and technical activities
Open in API
Filings indexed 418 across all filing types
Latest filing 2023-02-03 Major Shareholding Noti…
Country US United States of America
Listing US VERA

About Vera Therapeutics, Inc.

https://veratx.com/

Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological and rare diseases. The company's mission is to change the standard of care and improve patients' lives. Its lead product candidate is atacicept, a novel biologic molecule being developed for the treatment of IgA nephropathy (IgAN), a progressive autoimmune kidney disease. Vera Therapeutics aims to advance its pipeline of innovative therapies to address significant unmet medical needs within immunology.

Recent filings

Filing Released Lang Actions
SC 13G/A
Major Shareholding Notification
2023-02-03 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes a follow-on public offering, including details about the underwriting agreement, number of shares, price, gross proceeds, and closing conditions. There are no financial statements or detailed financial performance data included, only an announcement of a financing event. The document also includes exhibits related to the underwriting agreement and legal opinion. Given the focus on the public offering and financing details, this fits the category of Capital/Financing Update (CAP). The document length is 7188 characters, which is sufficient for a detailed announcement but does not contain comprehensive financial reports or earnings data. Therefore, the appropriate classification is CAP with high confidence.
2023-02-02 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a public offering of Class A common stock by Vera Therapeutics, Inc. It includes detailed information about the offering terms, underwriting, risk factors, use of proceeds, and company overview. The document is a registration and offering prospectus supplement, which is a type of capital raising disclosure. It is not a financial report, earnings release, management discussion, or any other report type. It is clearly an update on a financing transaction and capital raising activity. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, supporting a high confidence in this classification.
2023-02-02 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a preliminary prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act, related to an offering of $75 million of Class A common stock by Vera Therapeutics, Inc. It includes detailed information about the offering terms, risk factors, use of proceeds, underwriting, and company overview. The document is a registration and offering prospectus supplement, which is a type of capital raising disclosure. It is not a financial report, earnings release, or management discussion, nor is it a regulatory filing unrelated to capital raising. The presence of underwriting details, offering price, and securities description clearly indicates this is a Capital/Financing Update filing. The document length (15,000 characters) and content confirm it is the actual offering document, not just an announcement of a report publication or a regulatory filing. Therefore, the correct classification is Capital/Financing Update (CAP).
2023-02-01 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 1, 2023, reporting preliminary unaudited cash, cash equivalents, and marketable securities as of December 31, 2022. It explicitly states that the financial close process is not complete and the data is preliminary and unaudited. The document is short (4049 characters) and primarily provides an update on financial condition without full financial statements or detailed analysis. It is a current report providing an update on financial results but not a full quarterly or annual report. This fits the definition of an Earnings Release (ER) as it announces key financial highlights for a period (quarter ended December 31, 2022) but does not contain comprehensive financial statements or management discussion. Therefore, the appropriate classification is Earnings Release (ER).
2023-02-01 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 30, 2023, by Vera Therapeutics, Inc. It announces an update to topline results from a Phase 2b clinical trial and includes a presentation as an exhibit. The text explicitly states that the information is furnished under Item 7.01 Regulation FD Disclosure and that the presentation is attached as Exhibit 99.1. The document is primarily an announcement of clinical trial data updates and a presentation, not a full financial report or earnings release. It does not contain detailed financial statements or comprehensive management discussion. The document is a regulatory filing announcing clinical trial data updates and providing a presentation to investors and the public. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and disclosure that does not fit other specific categories like Earnings Release or Investor Presentation. The document length (10,257 characters) is sufficient to contain substantive information but it is still an 8-K current report focused on disclosure rather than a full report or earnings release.
2023-01-30 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.